Mitochondrial Disease Testing with CentoMito
Improve the lives of patients of all ages affected by mitochondrial diseases. Mitochondrial diseases are genetic conditions that occur when mitochondria fail to produce enough energy for the cell.
Establishing a Diagnosis As Soon as Possible
There is no cure for mitochondrial diseases, but several different treatment options and approaches can help reduce symptoms or delay or prevent the progression of the disease. CentoMito is CENTOGENE's targeted genetic testing for the diagnosis of mitochondrial diseases.
By targeting nuclear encoded genes as well as mitochondrial encoded genes, this panel provides a comprehensive test in patients with a demonstrated mitochondrial deficiency on biopsy material or a suspicion of mitochondrial disorders based on the patient’s symptoms.
What Are Mitochondrial Diseases?
Mitochondrial diseases are genetic conditions that occur when mitochondria fail to produce enough energy for the cell. Genetic mutations in the mitochondrial genome, or nuclear genes, encoding proteins that maintain the function of the mitochondria, causing symptoms mainly in the organs where energy consumption is high. These organs are eye, liver, kidney, pancreas, blood, inner ear, colon, skeletal muscle, heart and brain.
Mitochondrial diseases are estimated to affect 1 in 4,000 people.
What Tests for The Diagnosis of Mitochondrial Diseases Are Offered by CENTOGENE?
CENTOGENE offers two panels for the Diagnosis of mitochondrial diseases:
CentoMito Comprehensive
Covers the entire mitochondrial genome (CentoMito Genome) along with nuclear genes related to mitochondrial diseases (≥99.0% targeted regions covered at ≥20x). ≥ 15.0 % mitochondrial heteroplasmy can be confidently detected; CNV analysis included
CentoMito Genome
Covers all mitochondrial encoded genes (≥97.0% targeted regions covered at ≥200x). Includes NGS-based copy number variation analysis. ≥ 15.0 % mitochondrial heteroplasmy can be confidently detected; CNV analysis included
Who Should Get Tested for Mitochondrial Diseases?
- Individuals with clinical symptoms characteristic of a specific mitochondrial disorder such as progressive external ophthalmoplegia, muscle biopsy findings, stroke-like episodes, etc.
- Individuals with any progressive multisystem disorder of unknown etiology
- Individuals with multiple complex neurologic features or a single neurological symptom with other system involvement
- Children presenting with lactic acidosis
- Presymptomatic testing for at-risk family members
Test Results
- Positive result – indicates that a previously understood disease-causing mutation was identified. This result can help the physician to assess the risk of experiencing certain symptoms and indicate the best way how to treat the disease. Positive result may also identify family members at risk of having the mutation, and carrier testing may be recommended.
- Negative result – does not necessarily rule out a mitochondrial disorder, and the patient should be managed according to clinical symptoms. Possible reasons for a negative result could be that the patient may have a mutation in a gene not covered by the testing panel, or it could be a mutation which is not detectable with the performed test, or the patient does not have a mitochondrial disorder.
- Variant of unknown clinical significance (VUS) – indicates that we have identified a change in the DNA, but this change is not known to be associated with a disorder. To clarify the clinical significance of the variant, testing other family members may be helpful.
Resources
Scientific Publications
Increasing Disease Insights by Describing Large Patient Cohorts
A deep understanding of a specific rare disorder is usually hampered by the small size of available patient cohorts. CENTOGENE was able to leverage its Biodatabank to overcome this obstacle for […]
Related Webinars
CentoLCV – El nuevo estándar para detectar desequilibrios cromosómicos
Mira el webinar sobre CentoLCV™, nuestro nuevo análisis integral de variación de número de copias (CNV), y aprender por qué es el nuevo estándar para establecer diagnósticos moleculares más precisos […]
CentoLCV – The New Standard for Detecting Chromosomal Imbalances
Watch Dr. Peter Bauer, MD, Chief Genomic Officer at CENTOGENE, as he discusses CentoLCV, our comprehensive Large Copy number Variation (CNV) analysis, and why it is the new standard for establishing […]
Genetics in Parkinson’s Disease – Lessons from a Global Cohort
Join our next webinar discussing Parkinson’s Disease, one of the most common neurodegenerative disorders manifested by a broad spectrum of motor and non-motor features. Prof. Peter Bauer, MD, […]
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET